Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02556606 · ClinicalTrials.gov registry record · Phase 3
Ketamine for Treatment Resistant Late-Life Depression
A Phase 3 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 33
- Enrollment target
NCT02556606: Completed Phase 3 study, sponsored by VA Office of Research and Development.
NCT02556606 is a Phase 3 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02556606, a Phase 3 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effectiveness of a single infusion of ketamine (KET), to determine which dose is optimal 7 days after infusion using Bayesian Adaptive Randomization, and to learn about how ketamine works in the body and brain in persons with late-life treatment resistant depression.
Interventions
- DRUG Ketamine
- DRUG Midazolam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-10-01 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02556606
The ClinicalTrials.gov registry entry for NCT02556606 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT02556606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02556606 about?
NCT02556606 is a clinical study titled "Ketamine for Treatment Resistant Late-Life Depression". The purpose of this study is to examine the effectiveness of a single infusion of ketamine (KET), to determine which dose is optimal 7 days after infusion using Bayesian Adaptive Randomization, and to learn about how ketamine works in the body and brain in persons with late-life treatment resistant ...
What is the current status of trial NCT02556606?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 33 participants. The study started on 2015-10-01. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT02556606?
The interventions under investigation include: Ketamine (DRUG), Midazolam (DRUG).
Who is sponsoring clinical trial NCT02556606?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.